ClinicalTrials.gg
CompletedNCT03834519KEYLYNK-010Updated May 18, 2025Results posted

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

A Phase 3 interventional study of Pembrolizumab and Olaparib in Prostatic Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 193 sites in 20 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
793
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing pembrolizumab in Prostatic Neoplasms — 4 open to participants now, 8 under way, none of them phase 3. pembrolizumab · Prostatic Neoplasms.

Enrollment
4th of 20
793 · median 41
Started
2019
with 3 others
Phase 3
4 of 20
none open now
Registered
9th of 20
by date
Lead sponsor
5 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing pembrolizumab in Prostatic Neoplasms, this one is the 4th largest by enrollment, is one of 4 that started in 2019, is one of 4 in phase 3, and was the 9th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 20 studies testing pembrolizumab in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing pembrolizumab in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly (ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants with mCRPC who have failed to respond to either abiraterone acetate or enzalutamide (but not both) and to chemotherapy.

The primary study hypotheses are that the combination of pembrolizumab plus olaparib is superior to abiraterone acetate or enzalutamide with respect to:

  1. Overall Survival (OS) and
  2. Radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 as assessed by blinded independent central review (BICR)

As of Amendment 06, the Data Monitoring Committee (DMC) is no longer applicable. Participants still on treatment may have the option to continue receiving study intervention or SOC if they are deriving clinical benefit, until criteria for discontinuation are met. Participants who are still on study treatment and deriving clinical benefit will no longer have tumor response assessments by BICR. However, local tumor imaging assessments should continue per standard of care (SOC) schedule. In addition, electronic patient-reported outcome (ePRO) assessments will no longer be performed and biomarker samples will no longer be collected.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has - or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
  • Has prostate cancer progression while receiving androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before screening
  • Has current evidence of disease documented by bone lesions on bone scan and/or soft tissue disease shown by computed tomography/magnetic resonance imaging (CT/MRI)
  • Has received prior treatment with abiraterone acetate OR enzalutamide, but not both

    • Have disease that progressed during or after treatment with abiraterone acetate for either metastatic hormone-sensitive prostate cancer (mHSPC) or mCRP or enzalutamide for mCRPC for at least 8 weeks (at least 14 weeks for participants with bone progression)
    • Participants that received abiraterone acetate for mHSPC may not have received abiraterone acetate or enzalutamide for mCRPC
  • Have received docetaxel chemotherapy regimen for metastatic castration-resistant prostate cancer (mCRPC) and have had progressive disease during or after treatment with docetaxel
  • Has ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<2.0 nM)
  • If receiving bone resorptive therapy, including but not limited to bisphosphonates or denosumab, must have been receiving stable doses before randomization
  • Must agree to refrain from donating sperm during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention PLUS be abstinent from heterosexual intercourse OR must agree to use unless confirmed to be azoospermic
  • Contraception use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirement above, the local label requirements are to be followed.
  • Has provided tumor tissue from a fresh core or excisional (obtained within 12 months of screening) from soft tissue not previously irradiated. Samples from tumors progressing at a prior site of radiation are allowed. Participants with bone-only or bone-predominant disease may provide a bone biopsy sample
  • Has an (ECOG) performance status of 0 or 1 assessed within 7 days of randomization

Exclusion criteria

Exclusion Criteria:

  • Has a known additional that is progressing or has required active treatment in the last 3 years
  • Has an active disease that has required systemic treatment in the past 2 years
  • Has a history of (noninfectious) pneumonitis requiring , or has current pneumonitis
  • Has known active (HIV), virus (e.g., hepatitis B surface antigen reactive) or virus (HCV) infection (e.g., HCV RNA [qualitative] is detected)
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has a history of seizure or any condition that may predispose to seizure
  • Has a history of loss of consciousness within 12 months of screening
  • Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features suggestive of MDS/AML
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
  • Has (≥Grade 3) to pembrolizumab and/or any of its
  • Has known hypersensitivity to the components or excipients in olaparib, abiraterone acetate, prednisone or prednisolone, or enzalutamide
  • Has symptomatic congestive heart failure ( Class III or IV heart disease)
  • Has received an anticancer monoclonal antibody (mAb) before randomization
  • Has received prior treatment with olaparib or any other PARP inhibitor
  • Has received prior treatment with apalutamide or darolutamide
  • Has received prior treatment with enzalutamide or apalutamide for metastatic hormone-sensitive prostate cancer
  • Has used herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA (e.g., saw palmetto) before the date of randomization
  • Has received prior treatment with radium or other therapeutic radiopharmaceuticals for prostate cancer
  • Has received prior treatment with an , anti-PD-L1, or anti PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, or CD137)
  • Is currently receiving either strong or moderate inhibitors of cytochrome P450 [CYP] () that cannot be discontinued for the duration of the study
  • Has received a previous allogenic bone marrow transplant or double umbilical cord transplantation (dUCBT) or a solid organ transplant
  • Has received a within 30 days prior to the date of randomization
  • Is currently participating in or has participated in a study of an agent, or has used an investigational device, within 4 weeks before the date of randomization
  • Has a bone "superscan"
  • Is expecting to father children within the projected duration of the study, starting with the screening visit through 90 days after the last dose of study intervention
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
793 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Olaparib

    Participants will receive olaparib 600 mg as two 150 mg oral tablets twice daily (BID) continuously until progression PLUS on Day 1 of each 21-day cycle, pembrolizumab 200 mg by intravenous (IV) infusion for up to 35 cycles (approximately 2 years).

    Biological: Pembrolizumab · Drug: Olaparib

  • Active comparator
    Next-generation Hormonal Agent Monotherapy (NHA)

    Participants will receive a single NHA, which will be either abiraterone acetate (participants previously treated with enzalutamide) 1000 mg as two 500 mg or four 250 mg oral tablets once daily (QD) PLUS prednisone or prednisolone 10 mg as one 5 mg tablet BID until progression OR enzalutamide (participants previously treated with abiraterone acetate) 160 mg as four 40 mg oral tablets or capsules OR two 80 mg tablets QD until progression.

    Drug: Abiraterone acetate · Drug: Prednisone · Drug: Enzalutamide · Drug: Prednisolone

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method was used to estimate the survival curves.

    Time frame: Up to ~31 months

  2. Radiographic Progression-Free Survival (rPFS)

    rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (\>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG rules include new bone lesions. The rPFS per PCWG-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method was used to estimate the survival curves.

    Time frame: Up to ~26 months

Secondary outcomes

  1. Time to Initiation of the First Subsequent Anticancer Therapy (TFST)

    TFST is the time from randomization to initiation of the first subsequent anticancer therapy defined as the first anti-cancer treatment not part of the study arm for a given participant, or death, whichever occurs first. The nonparametric Kaplan-Meier method was used to estimate the survival curves.

    Time frame: Up to ~26 months

  2. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions per RECIST 1.1 and no evidence of disease (NED) bone scan) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1 and Non-PD, non-evaluable (NE), or NED bone scan or CR with non-PD or NE bone scan.) The percentage of participants who experienced CR or PR as assessed by BICR is presented.

    Time frame: Up to ~31 months

  3. Duration of Response (DOR)

    DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented.

    Time frame: Up to ~26 months

  4. Time to Prostate-Specific Antigen (PSA) Progression

    Time to PSA progression is defined as the time from randomization to PSA progression. PSA progression date is defined as the date of: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. The nonparametric Kaplan-Meier method was used to estimate the survival curves.

    Time frame: Up to ~31 months

  5. Time to First Symptomatic Skeletal-Related Event (SSRE)

    SSRE is defined as the time from randomization to the first symptomatic skeletal-related event, defined as whichever occurs first: * First use of external-beam radiation therapy (EBRT) to prevent or relieve skeletal symptoms; * Occurrence of new symptomatic pathologic bone fracture (vertebral or nonvertebral); * Occurrence of spinal cord compression; or * Tumor-related orthopedic surgical intervention

    Time frame: Up to ~31 months

  6. Time to Radiographic Soft Tissue Progression

    Time to radiographic soft tissue progression is defined as the time from randomization to radiographic soft tissue progression per soft tissue rule of PCWG-modified RECIST 1.1. Progression is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Time to radiographic soft tissue progression as assessed by BICR is presented.

    Time frame: Up to ~31 months

  7. Time to Pain Progression (TTPP)

    TTPP is defined as the time from randomization to pain progression as determined by Item 3 of the Brief Pain Inventory Short Form (BPI-SF) and by the Analgesic Quantification Algorithm (AQA) score. Pain progression is defined as: 1. For participants who are asymptomatic at baseline, a ≥2-point change from baseline in the average (4-7 days) BPI-SF item 3 score at 2 consecutive visits OR initiation of opioid use for pain 2. For participants who are symptomatic at baseline (average BPI-SF Item 3 score \>0 and/or currently taking opioids), a ≥2-point change from baseline in the average BPI-SF Item 3 score and an average worst pain score ≥4 and no decrease in average opioid use (≥1-point decrease in AQA score from a starting value of 2 or higher) OR any increase in opioid use at 2 consecutive follow-up visits. Participants who had more than 2 consecutive visits that were not evaluable for pain progression were censored at the last evaluable assessment.

    Time frame: Up to ~31 months

  8. Number of Participants Who Experience an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an adverse event are presented.

    Time frame: Up to ~55 months

  9. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE are presented.

    Time frame: Up to ~1461 Days

07

Results

Posted Apr 20, 2023

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Started529264
Treated526256
Completed00
Not completed529264
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject58
Withdrew: Death368174
Withdrew: Physician decision51
Withdrew: Sponsor decision14980

Outcome measures

PrimaryOverall Survival (OS)

Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method was used to estimate the survival curves.

Time frame:
Up to ~31 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Overall Survival (OS)15.8 (14.6 to 17.0)14.6 (12.6 to 17.3)
Statistical analysis
  • Pembrolizumab + Olaparib vs Next-generation Hormonal Agent Monotherapy (NHA) · Log Rank · p = 0.2616 · Hazard ratio (hr): 0.94 · 95% CI 0.77 to 1.14Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by measurable disease status and prior NHA treatment.
PrimaryRadiographic Progression-Free Survival (rPFS)

rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (\>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG rules include new bone lesions. The rPFS per PCWG-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method was used to estimate the survival curves.

Time frame:
Up to ~26 months
Reported as:
Median · Months
Radiographic Progression-Free Survival (rPFS)
MonthsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Radiographic Progression-Free Survival (rPFS)4.4 (4.2 to 6.0)4.2 (4.0 to 6.1)
Statistical analysis
  • Pembrolizumab + Olaparib vs Next-generation Hormonal Agent Monotherapy (NHA) · Log Rank · p = 0.5544 · Hazard ratio (hr): 1.02 · 95% CI 0.82 to 1.25Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by measurable disease status and prior NHA treatment.
SecondaryTime to Initiation of the First Subsequent Anticancer Therapy (TFST)

TFST is the time from randomization to initiation of the first subsequent anticancer therapy defined as the first anti-cancer treatment not part of the study arm for a given participant, or death, whichever occurs first. The nonparametric Kaplan-Meier method was used to estimate the survival curves.

Time frame:
Up to ~26 months
Reported as:
Median · Months
Time to Initiation of the First Subsequent Anticancer Therapy (TFST)
MonthsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Time to Initiation of the First Subsequent Anticancer Therapy (TFST)7.2 (6.7 to 8.1)5.7 (5.0 to 7.1)
Statistical analysis
  • Pembrolizumab + Olaparib vs Next-generation Hormonal Agent Monotherapy (NHA) · Hazard ratio (hr): 0.86 · 95% CI 0.71 to 1.03Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by measurable disease status and prior NHA treatment.
SecondaryObjective Response Rate (ORR)

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions per RECIST 1.1 and no evidence of disease (NED) bone scan) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1 and Non-PD, non-evaluable (NE), or NED bone scan or CR with non-PD or NE bone scan.) The percentage of participants who experienced CR or PR as assessed by BICR is presented.

Time frame:
Up to ~31 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Objective Response Rate (ORR)16.8 (12.3 to 22.1)5.9 (2.4 to 11.7)
Statistical analysis
  • Pembrolizumab + Olaparib vs Next-generation Hormonal Agent Monotherapy (NHA) · Difference in percentage: 10.9 · 95% CI 4.0 to 17.1
SecondaryDuration of Response (DOR)

DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented.

Time frame:
Up to ~26 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Duration of Response (DOR)8.1 (6.2 to 14.1)8.5 (5.2 to NA)
SecondaryTime to Prostate-Specific Antigen (PSA) Progression

Time to PSA progression is defined as the time from randomization to PSA progression. PSA progression date is defined as the date of: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. The nonparametric Kaplan-Meier method was used to estimate the survival curves.

Time frame:
Up to ~31 months
Reported as:
Median · Months
Time to Prostate-Specific Antigen (PSA) Progression
MonthsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Time to Prostate-Specific Antigen (PSA) Progression3.3 (3.0 to 3.5)3.5 (3.2 to 4.3)
Statistical analysis
  • Pembrolizumab + Olaparib vs Next-generation Hormonal Agent Monotherapy (NHA) · Hazard ratio (hr): 1.11 · 95% CI 0.89 to 1.38Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by measurable disease status and prior NHA treatment.
SecondaryTime to First Symptomatic Skeletal-Related Event (SSRE)

SSRE is defined as the time from randomization to the first symptomatic skeletal-related event, defined as whichever occurs first: * First use of external-beam radiation therapy (EBRT) to prevent or relieve skeletal symptoms; * Occurrence of new symptomatic pathologic bone fracture (vertebral or nonvertebral); * Occurrence of spinal cord compression; or * Tumor-related orthopedic surgical intervention

Time frame:
Up to ~31 months
Reported as:
Median · Months
Time to First Symptomatic Skeletal-Related Event (SSRE)
MonthsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Time to First Symptomatic Skeletal-Related Event (SSRE)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Olaparib vs Next-generation Hormonal Agent Monotherapy (NHA) · Hazard ratio (hr): 0.54 · 95% CI 0.38 to 0.78Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by measurable disease status and prior NHA treatment.
SecondaryTime to Radiographic Soft Tissue Progression

Time to radiographic soft tissue progression is defined as the time from randomization to radiographic soft tissue progression per soft tissue rule of PCWG-modified RECIST 1.1. Progression is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Time to radiographic soft tissue progression as assessed by BICR is presented.

Time frame:
Up to ~31 months
Reported as:
Median · Months
Time to Radiographic Soft Tissue Progression
MonthsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Time to Radiographic Soft Tissue Progression10.3 (8.3 to 12.3)6.4 (6.1 to 10.2)
Statistical analysis
  • Pembrolizumab + Olaparib vs Next-generation Hormonal Agent Monotherapy (NHA) · Hazard ratio (hr): 0.79 · 95% CI 0.62 to 1.00Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by measurable disease status and prior NHA treatment.
SecondaryTime to Pain Progression (TTPP)

TTPP is defined as the time from randomization to pain progression as determined by Item 3 of the Brief Pain Inventory Short Form (BPI-SF) and by the Analgesic Quantification Algorithm (AQA) score. Pain progression is defined as: 1. For participants who are asymptomatic at baseline, a ≥2-point change from baseline in the average (4-7 days) BPI-SF item 3 score at 2 consecutive visits OR initiation of opioid use for pain 2. For participants who are symptomatic at baseline (average BPI-SF Item 3 score \>0 and/or currently taking opioids), a ≥2-point change from baseline in the average BPI-SF Item 3 score and an average worst pain score ≥4 and no decrease in average opioid use (≥1-point decrease in AQA score from a starting value of 2 or higher) OR any increase in opioid use at 2 consecutive follow-up visits. Participants who had more than 2 consecutive visits that were not evaluable for pain progression were censored at the last evaluable assessment.

Time frame:
Up to ~31 months
Reported as:
Median · Months
Time to Pain Progression (TTPP)
MonthsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Time to Pain Progression (TTPP)13.5 (9.7 to NA)12.0 (10.1 to NA)
Statistical analysis
  • Pembrolizumab + Olaparib vs Next-generation Hormonal Agent Monotherapy (NHA) · Log Rank · p = 0.3643 · Hazard ratio (hr): 0.95 · 95% CI 0.72 to 1.26Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by measurable disease status and prior NHA treatment.
SecondaryNumber of Participants Who Experience an Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an adverse event are presented.

Time frame:
Up to ~55 months
Reported as:
Count of participants · Participants
Number of Participants Who Experience an Adverse Event (AE)
ParticipantsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Number of Participants Who Experience an Adverse Event (AE)518238
SecondaryNumber of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE are presented.

Time frame:
Up to ~1461 Days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
ParticipantsPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)9011

Adverse events

Collected over For All-Cause Mortality: from allocation up to ~55 months. For AEs from start of treatment up to ~55 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Olaparib372/529 (70.3%)179/526 (34%)495/526 (94.1%)
Next-generation Hormonal Agent Monotherapy (NHA)178/264 (67.4%)59/256 (23%)215/256 (84%)
Most frequent serious events
Showing 10 of 181
Most frequent serious events
EventPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
AnaemiaBlood and lymphatic system disorders20/5263/256
PneumoniaInfections and infestations15/5262/256
Urinary tract infectionInfections and infestations11/5264/256
Adrenal insufficiencyEndocrine disorders9/5261/256
HaematuriaRenal and urinary disorders3/5264/256
Back painMusculoskeletal and connective tissue disorders7/5262/256
PyelonephritisInfections and infestations3/5263/256
HyponatraemiaMetabolism and nutrition disorders1/5263/256
COVID-19Infections and infestations6/5261/256
DeathGeneral disorders5/5262/256
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)
AnaemiaBlood and lymphatic system disorders272/52636/256
NauseaGastrointestinal disorders223/52647/256
FatigueGeneral disorders188/52666/256
Decreased appetiteMetabolism and nutrition disorders155/52646/256
ConstipationGastrointestinal disorders108/52644/256
DiarrhoeaGastrointestinal disorders103/52621/256
ArthralgiaMusculoskeletal and connective tissue disorders99/52637/256
AstheniaGeneral disorders95/52627/256
Back painMusculoskeletal and connective tissue disorders85/52645/256
VomitingGastrointestinal disorders92/52618/256

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)Total
Mean69.9 ± 7.469.1 ± 7.369.6 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)Total
Female000
Male529264793
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)Total
Hispanic or Latino7132103
Not Hispanic or Latino441219660
Unknown or Not Reported171330
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)Total
American Indian or Alaska Native101
Asian10259161
Native Hawaiian or Other Pacific Islander112
Black or African American145
White419199618
More than one race101
Unknown or Not Reported415
Measurable Response Evaluation Criteria in Solid Tumors Version 1.1 Disease Status at Baseline
Measurable Response Evaluation Criteria in Solid Tumors Version 1.1 Disease Status at Baseline(Participants)Pembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)Total
RECIST Measurable: Yes244119363
RECIST Measurable: No285145430
Prior Use of NHA Treatment
Prior Use of NHA Treatment(Participants)Pembrolizumab + OlaparibNext-generation Hormonal Agent Monotherapy (NHA)Total
Abiraterone only289143432
Enzalutamide only240120360
Abiraterone and Enzalutamide011
08

Study locations

193 sites
  • St. Joseph Heritage Healthcare ( Site 0069)
    Fullerton, California 92835, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0081)
    Los Angeles, California 90404, United States
  • Sibley Memorial Hospital ( Site 0096)
    Washington, District of Columbia 20016, United States
  • Georgia Cancer Center at Augusta University ( Site 0026)
    Augusta, Georgia 30912, United States
  • Quincy Medical Group ( Site 0021)
    Quincy, Illinois 62301, United States
  • Tulane Cancer Center ( Site 0066)
    New Orleans, Louisiana 70112, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0005)
    Baltimore, Maryland 21287, United States
  • Chesapeake Urology Research Associates ( Site 0076)
    Towson, Maryland 21204, United States
  • Beth Israel Deaconess Medical Ctr. ( Site 0093)
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute ( Site 0033)
    Boston, Massachusetts 02215, United States
  • UMass Memorial Medical Center ( Site 0053)
    Worcester, Massachusetts 01655, United States
  • Barbara Ann Karmanos Cancer Institute ( Site 0077)
    Detroit, Michigan 48201, United States
  • Henry Ford Health System ( Site 0039)
    Detroit, Michigan 48202, United States
  • St. Vincent Frontier Cancer Center ( Site 0016)
    Billings, Montana 59102, United States
  • Nebraska Cancer Specialists ( Site 0034)
    Omaha, Nebraska 68130, United States
  • Comprehensive Cancer Centers of Nevada ( Site 0092)
    Las Vegas, Nevada 89169, United States
  • University of New Mexico Cancer Center ( Site 0048)
    Albuquerque, New Mexico 87131, United States
  • Memorial Medical Center ( Site 0095)
    Las Cruces, New Mexico 88011, United States
  • Associated Medical Professionals of NY ( Site 0060)
    Syracuse, New York 13210, United States
  • Duke Cancer Center Cary ( Site 0010)
    Cary, North Carolina 27511, United States
  • Gabrail Cancer Center-Research ( Site 0097)
    Canton, Ohio 44718, United States
  • The Urology Group- Cincinnati ( Site 0094)
    Cincinnati, Ohio 45212, United States
  • University Hospitals of Cleveland Seidman Cancer Center ( Site 0036)
    Cleveland, Ohio 44106, United States
  • Carolina Urologic Research Center ( Site 0070)
    Myrtle Beach, South Carolina 29572, United States
  • Huntsman Cancer Institute ( Site 0002)
    Salt Lake City, Utah 84112, United States
  • Virginia Cancer Institute ( Site 0052)
    Richmond, Virginia 23230, United States
  • Blue Ridge Cancer Care ( Site 0086)
    Roanoke, Virginia 24014, United States
  • Seattle Cancer Care Alliance ( Site 0079)
    Seattle, Washington 98109, United States
  • Froedtert and Medical College of Wisconsin ( Site 0045)
    Milwaukee, Wisconsin 53226, United States
  • Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)
    Berazategui, Buenos Aires B1884BBF, Argentina
  • Centro de Diagnostico Urologico ( Site 1008)
    Buenos Aires, Caba C1120AAT, Argentina
  • Hospital Britanico de Buenos Aires ( Site 1006)
    Buenos Aires, Caba C1280AEB, Argentina
  • Sanatorio Parque ( Site 1002)
    Rosario, Santa Fe S2000DSV, Argentina
  • Instituto de Investigaciones Metabolicas ( Site 1011)
    Buenos Aires, C1012AAR, Argentina
  • Hospital Aleman ( Site 1004)
    Buenos Aires, C1118AAT, Argentina
  • Instituto Medico Alexander Fleming ( Site 1010)
    Buenos Aires, C1426ANZ, Argentina
  • CEMAIC ( Site 1014)
    Cordoba, X5008HHW, Argentina
  • St. Vincent's Hospital ( Site 0158)
    Darlinghurst, New South Wales 2010, Australia
  • Macquarie University ( Site 0151)
    Macquarie University, New South Wales 2109, Australia
  • Port Macquarie Base Hospital ( Site 0153)
    Port Macquarie, New South Wales 2444, Australia
  • Calvary Mater Newcastle ( Site 0148)
    Waratah, New South Wales 2298, Australia
  • Southern Medical Day Care Centre ( Site 0160)
    Wollongong, New South Wales 2500, Australia
  • Royal Brisbane and Women s Hospital ( Site 0155)
    Herston, Queensland 4029, Australia
  • John Flynn Hospital & Medical Centre ( Site 0164)
    Tugun, Queensland 4224, Australia
  • Box Hill Hospital ( Site 0146)
    Box Hill, Victoria 3128, Australia
  • Peter MacCallum Cancer Centre ( Site 0152)
    Melbourne, Victoria 3000, Australia
  • Fiona Stanley Hospital ( Site 0162)
    Murdoch, Western Australia 6150, Australia
  • Ordensklinikum Linz GmbH Elisabethinen ( Site 0373)
    Linz, Oberosterreich 4020, Austria
  • Medizinische Universitat Graz ( Site 0374)
    Graz, Steiermark 8036, Austria
  • SCRI-CCCIT GesmbH ( Site 0371)
    Salzburg, 5020, Austria
  • Medizinische Universitaet Wien ( Site 0375)
    Wien, 1090, Austria
  • Hospital de Caridade de Ijui ( Site 1038)
    Ijui, Rio Grande Do Sul 98700-000, Brazil
  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021)
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035)
    Itajai, Santa Catarina 88301-215, Brazil
  • Hospital de Base de Sao Jose de Rio Preto ( Site 1022)
    Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil
  • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 1040)
    São Paulo, Sao Paulo 04014-002, Brazil
  • A.C. Camargo Cancer Center ( Site 1026)
    Sao Paulo, 01509-900, Brazil
  • Cross Cancer Institute ( Site 0110)
    Edmonton, Alberta T6G 1Z2, Canada
  • BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0113)
    Kelowna, British Columbia V1Y 5L3, Canada
  • BC Cancer-Vancouver Center ( Site 0112)
    Vancouver, British Columbia V5Z 4E6, Canada
  • Nova Scotia Health Authority QEII-HSC ( Site 0114)
    Halifax, Nova Scotia B3H 2Y9, Canada
  • William Osler Health System (Brampton Civic Hospital) ( Site 0121)
    Brampton, Ontario L6R 3J7, Canada
  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0116)
    Hamilton, Ontario L8V 5C2, Canada
  • Princess Margaret Cancer Centre ( Site 0107)
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102)
    Rimouski, Quebec G5L 5T1, Canada
  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105)
    Sherbrooke, Quebec J1H 5N4, Canada
  • CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0103)
    Quebec, G1R 2J6, Canada
  • Centro Investigación del Cáncer James Lind ( Site 1041)
    Temuco, Araucania 4780000, Chile
  • Rey y Oreilly Limitada ( Site 1048)
    Temuco, Araucania 4810148, Chile
  • Fundacion Arturo Lopez Perez ( Site 1049)
    Santiago, Region M. De Santiago 7500921, Chile
  • Pontificia Universidad Catolica de Chile ( Site 1047)
    Santiago, Region M. De Santiago 8330032, Chile
  • Bradford Hill Centro de Investigaciones Clinicas ( Site 1044)
    Santiago, Region M. De Santiago 8420383, Chile
  • C.H. de Saint Quentin ( Site 0481)
    Saint Quentin, Aisne 02321, France
  • Clinique Sainte Anne ( Site 0431)
    Strasbourg, Alsace 67000, France
  • Centre Jean Perrin ( Site 0434)
    Clermont-Ferrand, Auvergne 63011, France
  • Institut Paoli Calmettes ( Site 0419)
    Marseille, Bouches-du-Rhone 13009, France
  • CHU de Brest -Site Hopital Morvan ( Site 0441)
    Brest, Bretagne 29200, France
  • CHU Jean Minjoz ( Site 0423)
    Besancon, Doubs 25000, France
  • Institut Bergonie ( Site 0421)
    Bordeaux, Gironde 33076, France
  • Institut Claudius Regaud IUCT Oncopole ( Site 0418)
    Toulouse, Haute-Garonne 31059, France
  • Hopital Foch ( Site 0428)
    Suresnes, Hauts-de-Seine 92150, France
  • Institut Regional du Cancer de Montpellier - ICM ( Site 0443)
    Montpellier, Herault 34298, France
  • Institut De Cancerologie De L Ouest ( Site 0448)
    Saint Herblain, Loire-Atlantique 44805, France
  • Centre Hospitalier Regional du Orleans ( Site 0430)
    Orleans, Loiret 45100, France
  • Centre D Oncologie de Gentilly ( Site 0432)
    Nancy, Meurthe-et-Moselle 54100, France
  • Centre Leon Berard ( Site 0422)
    Lyon, Rhone 69373, France
  • C.H.U. Lyon Sud ( Site 0436)
    Pierre Benite, Rhone 69310, France
  • CHU Amiens Picardie Site Sud Amiens ( Site 0438)
    Amiens, Somme 80000, France
  • Institut Gustave Roussy ( Site 0416)
    Villejuif, Val-de-Marne 94800, France
  • Institut Sainte Catherine ( Site 0447)
    Avignon, Vaucluse 84000, France
  • Institut Mutualiste Montsouris ( Site 0446)
    Paris, 75014, France
  • Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304)
    Freiburg, Baden-Wurttemberg 79106, Germany
  • Universitaetsklinikum in Mannheim ( Site 0314)
    Mannheim, Baden-Wurttemberg 68167, Germany
  • Studienpraxis Urologie ( Site 0309)
    Nuertingen, Baden-Wurttemberg 72622, Germany
  • Universitaetsklinik fuer Urologie ( Site 0307)
    Tuebingen, Baden-Wurttemberg 72076, Germany
  • Universitaetsklinikum Erlangen ( Site 0303)
    Erlangen, Bayern 91054, Germany
  • Klinikum Rechts der Isar ( Site 0300)
    Muenchen, Bayern 81675, Germany
  • Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318)
    Nuernberg, Bayern 90419, Germany
  • Universitaetsklinikum Duesseldorf ( Site 0306)
    Duesseldorf, Nordrhein-Westfalen 40225, Germany
  • Krankenhaus der Barmherzigen Brueder Trier ( Site 0310)
    Trier, Rheinland-Pfalz 54292, Germany

Showing the first 100 of 193 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol. 2023 Aug 1;41(22):3839-3850. doi: 10.1200/JCO.23.00233. Epub 2023 Jun 8. PubMed 37290035 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Mar 2022, 34 months.

Results were first posted in Apr 2023, 1 year 1 month after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 34 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2019
First posted
Feb 8, 2019
StartActual
May 2, 2019
Primary completionActual
Mar 14, 2022
CompletionActual
Jan 27, 2024
Results first posted
Apr 20, 2023
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03834519
Responsible party
Sponsor
First posted
Feb 8, 2019
Start date
May 2, 2019
Primary completion
Mar 14, 2022
Completion
Jan 27, 2024
Results posted
Apr 20, 2023
Last update
May 18, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Olaparib

Start the discussion